Related Experiment Video
Updated: May 10, 2026
Echocardiography-guided Injection for Targeted and Reliable Intramyocardial Stem Cell Delivery in a Rat Model of Myocardial Infarction
Published on: July 25, 2025
Intracoronary abciximab in STEMI using local drug delivery catheter - single center experience
1Senior Consultant Cardiologist, Department of Cardiology, Apollo Hospitals, Greams Lane, Chennai 600 006, India.
Insights
Intracoronary abciximab via local drug delivery catheters improved microvascular obstruction in STEMI patients undergoing primary PCI. This localized therapy enhanced blood flow and vessel grading without increasing bleeding risk, offering a promising treatment strategy.
Area of Science:
- Cardiology
- Interventional Cardiology
Background:
- Microvascular obstruction can persist after primary PCI in STEMI patients, despite restored epicardial flow.
- Localized intracoronary pharmacotherapy offers higher drug concentrations compared to systemic administration.
- Atheromatous/thrombotic embolization and vasospasm contribute to persistent microvascular obstruction.
Purpose of the Study:
- To evaluate the efficacy of intracoronary abciximab delivered via a local drug delivery catheter in STEMI patients undergoing primary PCI.
- To assess the impact of this localized therapy on microvascular function.
Main Methods:
- Retrospective evaluation of 15 STEMI patients undergoing primary PCI between March 2011 and September 2012.
- Superselective intracoronary abciximab administration using a local drug delivery catheter.
- Assessment of Pre and Post TIMI flow and TMP grading with standard antiplatelet therapy.
Main Results:
- Mean patient age was 55 years.
- TIMI flow improved by 3 grades in 13 patients.
- TMP grading improved by 2 or 3 grades in all patients (14/15).
Conclusions:
- Superselective intracoronary abciximab significantly improves TMP grading in STEMI patients undergoing primary PCI.
- This approach enhances microvascular function without increasing bleeding risk.
- Further studies are needed to assess long-term outcomes, including infarct size reduction.
Background:
Despite restoration of epicardial flow during primary PCI in STEMI, microvascular obstruction may persist as a result of both atheromatous and thrombotic embolization and vasospasm. Compared with the systemic administration of IV pharmaco-therapies, highly localized administration of intracoronary pharmacotherapy may be associated with a several-hundred-fold increase in the local concentration of an agent in the epicardial artery and microcirculation. Despite restoration of epicardial flow during primary PCI in STEMI, microvascular obstruction may persist as a result of both atheromatous and thrombotic embolization and vasospasm. We are presenting our experience with use of intracoronary abciximab using local drug delivery catheter in STEMI patients.
Methods:
We retrospectively evaluated 15 patients presented to us with STEMI undergoing primary PCI between March 2011 and September 2012 who had super selective intracoronary abciximab using local drug delivery catheter. With standard antiplatelet therapy, both Pre and Post TIMI flow, TMP grading were assessed.
Results:
Mean age was 55 years. The TIMI flow increased by 3 grades in thirteen patients, TMP grading increased by 2 grades in five patients and by 3 grades in nine patients. Thus TIMI flow and TMP grading improved after super selective intracoronary abciximab.
Conclusion:
Super selective intracoronary abciximab using local drug delivery catheter during primary PCI in STEMI patients significantly improves TMP grading without increased risk of bleeding. This benefit is achieved even in patients without thrombus aspiration. We need to assess the long-term outcomes in the form of reduction in infarct size using this strategy in large group of patients.
Related Concept Videos
01:30Acute Coronary Syndrome I: Introduction
01:28Acute Coronary Syndrome IV: Interprofessional Care